Magnesium Phosphate, Tribasic, Pentahydrate.
Research-backed mineral with potential health benefits. Supplies magnesium and phosphate together, two minerals your body uses for energy transfer, nerve and muscle signalling, and for the mineral structure that makes bone rigid.
Reviewed March 2026
- Category
- Mineral
What Magnesium Phosphate, Tribasic, Pentahydrate is, and what it does.
- How much to take
- Aim for 200-400mg of *elemental* magnesium per day. This form isn't 100% magnesium, so you must check the 'elemental' value on the Supplement Facts panel.
- Time to feel it
- Two to four weeks for magnesium stores to fill. The change turns up on a blood panel and in steadier muscle comfort rather than as something you notice on the day.
- The first dose
- Probably nothing. Some people might get a slight gut rumble. The real benefits need a week or more to build up in your system.
- With regular use
- Correcting a deficiency can lead to better sleep, fewer muscle cramps, and a calmer nervous system. Standard magnesium benefits.
- How well tolerated
- Generally well tolerated. The main side effect is loose stools if you overdo it. That's your body's built-in signal to back off the dose. The usual kidney caution applies.
- How it feels
- A subtle unwinding effect over time. It's not a sedative. It just helps take the edge off physical tension and might help you relax before bed.
- The overlooked benefit
- It is one of the few magnesium sources that also carries phosphate, the partner ion to calcium in bone mineral, so it feeds two mineral pools from one powder.
200 to 400mg a day is where Magnesium Phosphate, Tribasic, Pentahydrate works.
Source: NIH Office of Dietary Supplements + Rosanoff 2012 meta-analysis
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Magnesium Phosphate, Tribasic, Pentahydrate is documented in the library; the clinical read is in the queue. Nothing about the strength of the research prints until the read is done.
- Magnesium repletion and statusRandomised trial
- Bone mineral density measuresCohort study
- Normal muscle and nerve functionNarrative review
- Gastric acid bufferingNarrative review
- Acid dependent release of free magnesium ionIn vitro study
Questions people ask about Magnesium Phosphate, Tribasic, Pentahydrate.
- Is this the best kind of magnesium?
- Nope. It's okay, but forms like glycinate and malate are usually better absorbed and gentler on the stomach.
- Will magnesium phosphate give me diarrhea?
- It can. It has a higher chance of causing loose stools than glycinate, but generally less than the notorious magnesium oxide.
- Why is 'phosphate' in it?
- It's a salt made from magnesium and phosphoric acid. You get a bit of phosphorus too, but phosphorus deficiency is very rare.
- When should I take it?
- With a meal to reduce the chance of stomach upset. Taking it an hour before bed is common for sleep support.
- What does 'tribasic' mean?
- It's a chemistry term describing its molecular structure. You can safely ignore it.
- Is this different from other magnesiums?
- Yes. The salt it's bound to affects how well it's absorbed and its side effects. This one is a middle-of-the-road option.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Tribasic magnesium phosphate delivers phosphate along with the magnesium, so it adds to total phosphate load rather than sitting outside it. Phosphate and magnesium form poorly soluble complexes at intestinal pH, which is part of why this salt dissolves slowly. Anyone already taking a separate phosphate source is stacking two contributions to the same pool.
Pyridoxal kinase, the enzyme that converts pyridoxine to its active phosphate form, is a magnesium-ATP dependent enzyme. Supplying the already-phosphorylated vitamer bypasses that step. The two are frequently formulated together because magnesium status affects how much active B6 a body generates from the plain vitamin.
Tribasic magnesium phosphate has low water solubility and depends on stomach acid to liberate free magnesium ions. An acidifying agent lowers gastric pH and increases the dissolved fraction available for absorption. This matters more for a tribasic phosphate salt than for a soluble organic salt such as citrate or glycinate.
Bicarbonate raises gastric pH, and a mineral salt that needs acid to dissolve gives up less free ion at higher pH. Taking an alkalinising agent at the same time as this salt therefore reduces the dissolved magnesium fraction. Separating the two in time is the usual answer, and the same logic applies to any acid-suppressing agent.
Activated charcoal is non-selective and adsorbs minerals along with everything else in the lumen. Taken with a mineral salt it reduces the amount available for absorption. Spacing by several hours is standard practice with charcoal and any nutrient.
The galacturonic acid units in pectin are negatively charged at intestinal pH and bind divalent cations including magnesium and calcium. Binding within the gel phase lowers the free ion concentration available at the absorptive surface. Some of the bound mineral is released again when colonic bacteria ferment the pectin, so the effect is a shift in where absorption happens rather than a total loss.
Guar gum forms a viscous layer that slows diffusion of dissolved ions to the intestinal wall. For an already poorly soluble salt this compounds the limiting step. The interaction is about rate and contact rather than chemical binding, and it fades as the gum is fermented in the colon.
Glucomannan hydrates to a high-viscosity gel that entraps luminal contents. Minerals held in that gel reach the brush border more slowly and less completely within the absorptive window. As with other viscous fibres, taking the mineral apart from the fibre dose sidesteps the issue.
Bentonite is a layered aluminosilicate whose interlayer sites exchange cations, and magnesium is one of the cations it will take up. Co-ingestion therefore removes a share of the mineral from solution. Clays are used for their binding capacity, so the interaction is inherent to what they do rather than incidental.
Nothing specific on file for Magnesium Phosphate, Tribasic, Pentahydrate. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Magnesium Phosphate, Tribasic, Pentahydrate actually does.
Magnesium is required as the Mg-ATP complex by every ATP-dependent kinase, which is why it is a cofactor for several hundred enzymes spanning glycolysis, nucleotide synthesis and protein phosphorylation.
Tribasic magnesium phosphate, Mg3(PO4)2, has low aqueous solubility, so the amount of free magnesium ion released depends on gastric acid exposure rather than on the dose alone.
This salt supplies both magnesium and phosphate, so it contributes to two mineral pools at once, unlike organic magnesium salts whose counter-ion is metabolised.
Magnesium ions block the NMDA receptor channel in a voltage-dependent manner, a textbook feature of excitatory neurotransmission and one of the reasons magnesium status is discussed in the context of normal neuronal signalling.
Where Magnesium Phosphate, Tribasic, Pentahydrate comes from.
Magnesium from mined rock or from seawater is reacted with phosphoric acid. The solid that forms is washed, dried carefully so that it keeps the right amount of water locked into its crystals, and ground into a powder.
From a mineral source, then refined and usually bound to a carrier so the body can take it up.
Magnesium oxide or hydroxide, obtained by calcining magnesite ore or by precipitating magnesium hydroxide from seawater or brine, is paired with food-grade phosphoric acid made from mined phosphate rock.
The magnesium source is reacted with phosphoric acid under controlled pH and temperature, and the tribasic salt precipitates out of solution as the reaction approaches neutrality.
The precipitate is filtered and washed to remove unreacted acid and soluble impurities carried over from the ore, with heavy metal limits set by the food-grade specification.
Drying conditions are controlled to hold the pentahydrate rather than driving off crystal water, and the material is assayed for magnesium content, phosphate and loss on drying.
The dried cake is milled to a defined particle size distribution, which governs flow, dispersion and the surface area available for dissolution.
Getting Magnesium Phosphate, Tribasic, Pentahydrate from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
Magnesium Phosphate, Tribasic, Pentahydrate is a form of Magnesium.
Magnesium Phosphate, Tribasic, Pentahydrate is the phosphate form of Magnesium. Same mineral, bound to a different partner, so absorption and feel differ from form to form.
See the other 16 forms
The essence, in one line each.
- Pooling 34 trials, magnesium lowered systolic blood pressure by about 2 mmHg.Meta-analysis. Zhang et al., 2016 (Hypertension). PMID 27402922 ↗
- Across 3 trials in older adults, it shortened the time to fall asleep by about 17 minutes.Systematic review. Mah and Pitre, 2021 (BMC Complement Med Ther). PMID 33865376 ↗
- Across 10 trials, magnesium reduced how often migraine attacks struck.Meta-analysis. Chiu et al., 2016 (Pain Physician). PMID 26752497 ↗
- In 46 older adults, eight weeks of magnesium improved insomnia scores against placebo.Randomised trial. Abbasi 2012 (older adults with insomnia). PMID 23853635 ↗
- Across 38 trials with 2,709 adults at a median 365 mg a day for 12 weeks, magnesium lowered systolic blood pressure by about 2.8 mmHg and diastolic by about 2.1 mmHg, with larger reductions in people who had low blood magnesium.Meta-analysis. Argeros et al., 2025 (Hypertension). PMID 41000008 ↗
- Pooling over 20 trials, magnesium raised HDL cholesterol by about 1.2 mg/dL and showed no detectable change in total cholesterol, LDL or triglycerides, with very high heterogeneity between studies.Meta-analysis. Hariri et al., 2025 (Nutrition Journal). PMID 39905454 ↗
- Reviewing trials across different activity types, magnesium was linked to less muscle soreness and better recovery, and the authors put the requirement of people training intensely 10 to 20 percent above that of sedentary people, without pooling an effect size.Systematic review. Tarsitano et al., 2024 (Journal of Translational Medicine). PMID 38970118 ↗
- In 65 older adults with high blood sugar and low blood magnesium, oral magnesium raised plasma magnesium by 0.056 mmol/L and lowered fasting glucose by about 0.50 mmol/L, with no detectable change in HbA1c, insulin or insulin resistance.Randomised trial. Yang et al., 2026 (Frontiers in Nutrition). PMID 41756632 ↗
- Pooling 24 trials with 1,325 adults who had high blood sugar, magnesium lowered fasting glucose by 0.20 mM, HbA1c by 0.22 percent, systolic blood pressure by 7.69 mmHg and diastolic by 2.71 mmHg, at typical doses near 300 mg a day for about four months.Meta-analysis. Xu et al., 2022 (Frontiers in Nutrition). PMID 36741996 ↗
- Magnesium supplementation did not produce a detectable reduction in serum calciprotein crystallisation or arterial stiffness in this randomised trial, which is a failure to detect a difference rather than evidence of no effect.Randomised trial. Meer et al., 2026 (The American journal of clinical nutrition). PMID 41903889 ↗
- A randomised controlled trial measured whether magnesium supplementation changed serum brain-derived neurotrophic factor, a blood marker rather than an outcome, alongside cognitive performance in adults.Randomised trial. Noor et al., 2026 (East Asian archives of psychiatry). PMID 42374947 ↗
- Across 18 double-blind randomised trials, oral magnesium lowered fasting blood glucose in adults with raised blood sugar (standardised mean difference -0.40) and improved two-hour glucose readings in adults at raised risk (standardised mean difference -0.35).Systematic review. Veronese et al., 2016 (European Journal of Clinical Nutrition). PMID 27530471 ↗
- In older adults with night-time leg cramps, magnesium showed no detectable difference from placebo in weekly cramp frequency at four weeks (mean difference -0.18 cramps per week, 5 studies, 307 participants), which is a failure to detect a benefit rather than evidence that none exists.Systematic review. Garrison et al., 2020 (Cochrane Database of Systematic Reviews). PMID 32956536 ↗
- A Cochrane review assembling the randomised trials of magnesium supplementation reporting recurrent headache attack frequency; it is the current systematic summary of that trial set, and the review's own pooled estimate and certainty rating are the figures to read.Systematic review. Rodriguez et al., 2025 (Cochrane Database of Systematic Reviews). PMID 41216917 ↗
- The pooled analysis reported improvement in rated low-mood symptom scores with magnesium supplementation; scores on a rating scale are the endpoint, and the contributing trials were small.Systematic review. Moabedi et al., 2023 (Frontiers in Psychiatry). PMID 38213402 ↗
- Reports symptom-scale change when magnesium was added alongside an existing prescribed antidepressant; a single trial reporting a rated scale, and the medication is doing part of the work by design.Randomised trial. Walyddaini et al., 2026 (East Asian Archives of Psychiatry). PMID 41916937 ↗
- Pools randomised trials of magnesium supplementation in pregnancy reporting glucose and insulin measures; the endpoints are glycaemic markers rather than birth or infant outcomes.Meta-analysis. Luo et al., 2024 (European Journal of Obstetrics, Gynecology, and Reproductive Biology). PMID 38128389 ↗
- A second pooled analysis over the same kind of trials, reporting glycaemic status measures with magnesium supplementation during pregnancy; markers again, and the included trials are few and small.Meta-analysis. Tan et al., 2022 (Gynecological Endocrinology). PMID 34907820 ↗
- A nonrandomised clinical trial reporting rapid heart-rhythm episode counts under a magnesium supplementation protocol; without randomisation the supplement cannot be separated from the surrounding care.Open-label trial. Goulden et al., 2026 (JAMA Internal Medicine). PMID 41359319 ↗
- A pilot randomised trial using quantitative sensory testing thresholds during magnesium supplementation in adults with reduced bone density; measured sensory thresholds are the endpoint and a pilot sample cannot settle the question.Randomised trial. Pickering et al., 2026 (Aging Clinical and Experimental Research). PMID 41566091 ↗
- Compared when magnesium was taken and tracked urinary chemistry in adults with a history of urinary stone formation; urinary chemistry is a marker of risk handling, not an event count.Randomised trial. Sharbaugh et al., 2025 (Clinical Nephrology). PMID 39913253 ↗
- Adding magnesium to a blood-brain-barrier-integrated neural culture model changed cortical layering and neuronal differentiation markers; a cell model result that grounds mechanism and is not human evidence.In vitro study. Castiglioni et al., 2026 (Biomedicines). PMID 42351670 ↗
These are the studies our verdict leans on, chosen from the 32,306 we read for Magnesium Phosphate, Tribasic, Pentahydrate. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.